ImmuPharma plc (LON:IMM – Get Free Report) dropped 18% during trading on Wednesday . The stock traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.84 ($0.06). Approximately 61,560,121 shares changed hands during mid-day trading, an increase of 142% from the average daily volume of 25,488,205 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Trading Down 3.7 %
The firm has a market cap of £21.65 million, a P/E ratio of -520.00 and a beta of 1.53. The business’s 50-day moving average is GBX 2.06 and its two-hundred day moving average is GBX 1.83.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- How to Read Stock Charts for Beginners
- Nebius Group: Market Overreaction or Real AI Disruption?
- Compound Interest and Why It Matters When Investing
- The Best Way to Invest in Gold Is…
- What is the FTSE 100 index?
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
